In:
Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 14, No. 3 ( 2008-02-01), p. 710-714
Kurzfassung:
Purpose: To evaluate serum C-reactive protein (CRP) as prognostic variable in patients with epithelial ovarian cancer (EOC). Experimental Design: In a multicenter study, preoperative serum CRP was evaluated in 623 patients with EOC. Results were correlated with clinical data. Results: Mean (SD) preoperative serum CRP was 3.6 (4.8) mg/dL. Serum CRP was significantly associated with International Federation of Gynecologists and Obstetricians stage (P & lt; 0.001) and postoperative residual tumor mass (P & lt; 0.001) but not with histologic grade (P = 0.1) and type (P = 0.7), patients' age (Pearson's correlation coefficient = 0.05; P = 0.2), and serum CA 125 (Pearson's correlation coefficient = 0.02; P = 0.6). Patients with platinum-resistant EOC had significantly higher CRP serum levels compared with patients with platinum-sensitive EOC [6.0 (6.6) mg/dL versus 2.8 (3.8) mg/dL; P & lt; 0.001]. Higher International Federation of Gynecologists and Obstetricians stage (P & lt; 0.001), presence of postoperative residual tumor mass (P & lt; 0.001), tumor grade (P = 0.001), serum CA 125 (P = 0.03), and serum CRP (P = 0.001) were independently associated with overall survival. Patients with serum CRP ≤1 mg/dL versus & gt;1 mg/dL had an overall 5-year survival of 82% versus 58.5% (P & lt; 0.001). Conclusion: Serum CRP can be seen as a novel, widely available independent prognostic variable of ovarian cancer.
Materialart:
Online-Ressource
ISSN:
1078-0432
,
1557-3265
DOI:
10.1158/1078-0432.CCR-07-1044
Sprache:
Englisch
Verlag:
American Association for Cancer Research (AACR)
Publikationsdatum:
2008
ZDB Id:
1225457-5
ZDB Id:
2036787-9
Permalink